PTK7 × TROP2 Bispecific ADC (BCG033)

Asset ID: BCG033
Targets: PTK7 × TROP2
  • Aliases:
  • PTK7: CCK-4, CCK4; TROP2: TACSTD2, EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1
  • Modality:
  • Bispecific ADC (BsADC)
  • Payload Design:
  • vcMMAE or BLD1102 (proprietary linker–payload system containing BCPT02, a TOP1 inhibitor payload)
  • Development Stage:
  • Preclinical
  • Indications:
  • Non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), ovarian cancer, colorectal cancer, gastric cancer, esophageal cancer, cervical cancer
  • Key Differentiation:
  • Combines PTK7-mediated tumor selectivity with a tuned TROP2 arm to support broader coverage of heterogeneous tumors, efficient internalization and payload delivery, and strong pan-tumor preclinical efficacy
  • Partnership Opportunity:
  • Available for licensing and co-development
データパッケージを取得 会議予約
https://cdn.biocytogen.com/web/backend/upload/asset/image/BCG033/20260909222714723864.png (BCG033) banner

このページで

  • PTK7 × TROP2 Bispecific ADC Asset Highlights
  • Preclinical Data
  • Partnership Opportunities
  • FAQs

ポスター

すべて表示

    Related Platforms and Resources

    BCG033: A PTK7 × TROP2 Bispecific ADC for Heterogeneous Solid Tumors

    Dual-Target ADC Strategy for Tumor Selectivity and Broader Coverage

    • TROP2-targeted therapeutic rationale: TROP2 (TACSTD2) is a clinically validated ADC target broadly expressed across epithelial cancers, including triple-negative breast cancer (TNBC), HR+/HER2− breast cancer, and non-small cell lung cancer (NSCLC). However, TROP2 expression in normal tissues presents an on-target, off-tumor toxicity risk that limits the therapeutic window of conventional TROP2-targeted ADCs.
    • PTK7-mediated cooperative internalization: PTK7 (CCK-4) is frequently overexpressed in multiple solid tumors and co-expressed with TROP2, providing complementary tumor recognition and enabling more selective targeting of tumor cells.
    • Optimized TROP2 engagement: BCG033 incorporates a tuned TROP2-binding arm with reduced monovalent internalization activity, designed to limit cellular uptake in TROP2-only settings while preserving efficient internalization through cooperative PTK7/TROP2 engagement on dual-positive tumor cells.
    • Competitive differentiation: BCG033 combines PTK7-mediated tumor selectivity with a tuned TROP2 arm to overcome tumor heterogeneity, minimize TROP2-associated toxicity risk, and enhance precision payload delivery. Supported by superior preclinical efficacy, BCG033 is positioned as a differentiated pan-tumor bispecific ADC candidate.

    RenLite® Fully Human Common Light Chain Antibody Backbone

    Built on the RenLite® platform, BCG033 utilizes common light chain technology to eliminate heavy/light chain mispairing, ensure seamless assembly, simplify manufacturing, and provide a developable antibody backbone for the PTK7 × TROP2 bispecific ADC drug development.

    Dual Linker–Payload Options for ADC Drug Development

    BCG033 has been evaluated with two linker–payload formats to support different ADC development strategies: vcMMAE in earlier studies and Biocytogen’s proprietary BLD1102 linker–payload system, which contains BCPT02, a topoisomerase I (TOP1) inhibitor payload.

    • BLD1102 linker–payload design: BCPT02 is designed for high potency and strong bystander killing, while the BLD1102 linker is engineered for hydrophilicity, controlled payload release, and high circulation stability.
    • Payload strategy: The use of both vcMMAE and BLD1102 demonstrates the flexibility of the BCG033 antibody backbone across different linker–payload formats. Subsequent studies with BCG033-BLD1102 showed strong antitumor activity in PDX models, supporting BLD1102 as a differentiated payload option for continued ADC development.

    Excellent Preclinical Performance

    • PTK7 and TROP2 co-expression across multiple cancer types supports a dual-target ADC strategy for broader tumor coverage in antigen-heterogeneous solid tumors (Figure 1).
    • BCG033 bispecific antibody showed antigen-dependent binding across variable PTK7/TROP2 expression levels, while balanced target affinity and human–cynomolgus monkey cross-reactivity support effective dual-target engagement and translational evaluation (Figure 2).
    • BCG033 bispecific antibody showed efficient internalization across heterogeneous target-expression profiles, supporting enhanced, tumor-selective intracellular payload delivery (Figure 3).
    • BCG033 demonstrated stronger antitumor efficacy than parental ADCs and their combination in PDX models, and outperformed benchmark ADCs including cofetuzumab pelidotin (PTK7 ADC), Dato-DXd, and sacituzumab govitecan (TROP2 ADCs) (Figure 4 & Figure 5).

    Potential Indications

    BCG033 is being evaluated as a PTK7 × TROP2 bispecific ADC drug development asset for solid tumors. Potential development areas include non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), ovarian cancer, colorectal cancer, gastric cancer, esophageal cancer, and cervical cancer.

    Preclinical Data Highlights Supporting BCG033 PTK7 × TROP2 Bispecific ADC Drug Development

    The preclinical data package for BCG033, generated from Biocytogen’s internal studies, demonstrates a differentiated PTK7 × TROP2 bispecific ADC profile characterized by broad target co-expression across solid tumors, antigen-dependent binding, and efficient internalization across heterogeneous target-expression patterns. BCG033 also showed enhanced antitumor efficacy relative to parental ADCs in PDX models, with activity favored by PTK7 and TROP2 co-expression and evidence of synergistic efficacy with different payload formats. Together, these findings support the potential of BCG033 to improve tumor coverage, payload delivery, and antitumor efficacy in heterogeneous solid tumors.

    PTK7 and TROP2 Are Co-expressed Across Multiple Solid Tumor Types

    TCGA expression plots showing co-expression of PTK7 and TROP2 across non-small cell lung, breast, bladder, ovarian, prostate, and colorectal cancers.

    Figure 1. Co-expression analysis of PTK7 and TROP2 across TCGA tumor datasets. PTK7 and TROP2 showed overlapping expression patterns in multiple solid tumor types, including non-small cell lung cancer (NSCLC), breast cancer, bladder cancer, ovarian cancer, prostate cancer, and colorectal cancer, supporting the rationale for a dual-targeting strategy across broad patient populations.
    (Note: The co-expression percentage of PTK7 and TROP2 was extrapolated from separated literature reports.)
    In addition, RNA-sequencing analysis also showed PTK7 and TROP2 co-expression across multiple tumor cell lines, including triple-negative breast, lung, ovarian, colorectal, esophageal, and gastric cancer models.

    BCG033 Shows Broad and Selective Binding Across Heterogeneous Tumor Cells

    Binding curves showing BCG033 recognition of A431, NCI-N87, NCI-H226, and NUGC4 tumor cells with different PTK7 and TROP2 expression profiles.

    Figure 2. Binding analysis of the PTK7 × TROP2 bispecific antibody across tumor cell lines. BCG033 showed strong binding to A431 skin cancer cells (PTK7high/TROP2high), NCI-N87 gastric cancer cells (PTK7low/TROP2high), NCI-H226 lung cancer cells (PTK7moderate/TROP2negative), and NUGC4 gastric cancer cells (PTK7negative/TROP2moderate), while showing no binding to double-negative cells. These findings support broad coverage of antigen-heterogeneous tumors with antigen-dependent selectivity.
    In addition, BCG033 features balanced affinity for PTK7 and TROP2 and cross-reactivity with the corresponding human and cynomolgus monkey targets, supporting effective dual-target engagement and translational evaluation.

    BCG033 Demonstrates Efficient Internalization Across PTK7/TROP2 Expression Levels

    Internalization curves comparing BCG033 with parental antibody formats in A431, NCI-N87, NCI-H226, and NUGC4 tumor cells with different PTK7 and TROP2 expression levels.

    Figure 3. Internalization kinetics of the PTK7 × TROP2 bispecific antibody across tumor cell lines. BCG033 demonstrated efficient internalization in tumor cells with varying PTK7 and TROP2 expression levels, supporting effective intracellular payload delivery across heterogeneous target-expression profiles. Monovalent (mv) parental antibody formats showed reduced internalization, particularly for the TROP2 arm, indicating that the bispecific format enhances cellular uptake and may increase tumor selectivity and reduce on-target toxicity.

    BCG033 Demonstrates Tumor-Selective and Synergistic Antitumor Efficacy in PDX Models

    PDX tumor growth curves showing superior efficacy of BCG033 versus parental ADCs in breast cancer.

    Figure 4. Antitumor efficacy of BCG033 across PDX models with different target-expression profiles. (A) In the BP1395 breast cancer PDX model, BCG033 conjugated with the BLD1102 TOP1 inhibitor linker–payload system showed superior efficacy compared with parental ADCs. Superior or comparable efficacy was also observed across additional PTK7- and TROP2-expressing PDX models, supporting broad potential in tumors co-expressing both targets. (B) In the BP0508 (PTK7negative/TROP2high) NSCLC PDX model, BCG033 showed reduced efficacy, indicating that enhanced antitumor activity is favored by PTK7 and TROP2 co-expression and supporting the tumor selectivity of the bispecific design. (C) In the BP0595 TNBC PDX model, the PTK7 × TROP2-vcMMAE bispecific ADC achieved greater tumor growth inhibition than parental monoclonal ADCs administered alone or in combination, supporting a synergistic effect of the bispecific format and its potential to address tumor heterogeneity.

    Tumor growth curves showing superior antitumor efficacy of BCG033 compared with benchmark ADCs in BP0595 TNBC and BP1013 gastric cancer PDX models.

    Figure 5. Antitumor efficacy of BCG033 in the BP0595 TNBC and BP1013 gastric cancer PDX models. BCG033 demonstrated greater tumor growth inhibition than benchmark analogs—including the PTK7 ADC cofetuzumab pelidotin and the TROP2 ADCs datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan—in both models, supporting the differentiated in vivo efficacy and broad therapeutic potential of the PTK7 × TROP2 bispecific ADC strategy.

    Biocytogen welcomes partnership discussions to further evaluate this PTK7 × TROP2 bispecific ADC asset.

    Frequently Asked Questions (FAQs) About BCG033 PTK7 × TROP2 Bispecific ADC

    1. What makes BCG033 a differentiated PTK7 × TROP2 bispecific ADC?

    BCG033 combines PTK7-mediated tumor selectivity with a tuned TROP2 arm to address two major challenges of single-target ADCs: antigen heterogeneity and normal-tissue exposure. By enabling dual-target engagement and efficient internalization in PTK7/TROP2-expressing tumor cells, BCG033 is designed to broaden tumor coverage while supporting more tumor-selective payload delivery.

    2. How does the tuned TROP2 arm support tumor selectivity?

    Single-target TROP2 ADCs may be limited by on-target, off-tumor toxicity because TROP2 is also expressed in normal tissues. BCG033 incorporates a TROP2 arm selected for reduced monovalent internalization, helping limit cellular uptake in TROP2-only settings while preserving efficient engagement and internalization through PTK7 co-binding in dual-positive tumor cells. This design supports more tumor-selective payload delivery in PTK7/TROP2 co-expressing tumors.

    3. How does RenLite® support BCG033 bispecific ADC development?

    RenLite® provides a fully human common light chain antibody backbone for PTK7 × TROP2 bispecific ADC engineering. This design helps reduce heavy/light chain mispairing, supports correct bispecific antibody assembly, simplifies manufacturing, and improves downstream ADC developability.

    4. What linker–payload options are available for BCG033?

    BCG033 has been evaluated with vcMMAE in earlier studies and with Biocytogen’s proprietary BLD1102 linker–payload system in subsequent development. BLD1102 contains BCPT02, a topoisomerase I (TOP1) inhibitor payload designed for high potency and bystander-killing potential, together with a hydrophilic linker engineered for controlled payload release and circulation stability. This design supports ADC developability and systemic payload delivery.

    5. Which indications may be relevant for BCG033 development?

    BCG033 is being evaluated for PTK7- and/or TROP2-expressing solid tumors. Potential development areas include non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), ovarian cancer, colorectal cancer, gastric cancer, esophageal cancer, and cervical cancer. Preclinical activity across breast, gastric, colorectal, and lung tumor models supports its broader pan-tumor development potential.

     

    References